Initiative recently coordinated a multiinstitutional study that evaluated methodologies that are widely used for defining the N-glycan content in glycoproteins. The study convincingly endorsed mass spectrometry as the technique of choice for glycomic profiling in the discovery phase of diagnostic research. The present study reports the extension of the Human Disease Glycomics/Proteome Initiative's activities to an assessment of the methodologies currently used for O-glycan analysis. Three samples of IgA1 isolated from the serum of patients with multiple myeloma were distributed to 15 laboratories worldwide for O-glycomics analysis. A variety of mass spectrometric and chromatographic procedures representative of current methodologies were used. Similar to the previous N-glycan study, the results convincingly confirmed the pre-eminent performance of MS for O-glycan profiling. Two general strategies were found to give the most reliable data, namely direct MS analysis of mixtures of permethylated reduced glycans in the positive ion mode and analysis of native reduced glycans in the negative ion mode using LC-MS approaches. In addition, mass spectrometric methodologies to analyze
evaluation of methodologies that are widely used for defining the N-glycan content in glycoproteins (1) . Twenty laboratories around the world participated in the study in which the glycosylation of standard samples of transferrin and IgG was characterized by a variety of chromatographic and mass spectrometric techniques. Two clear messages emerged from this study. First, there was significant variance among the data sets from laboratories using chromatographic profiling that was likely due to incomplete derivatization with the fluorophores that had been used to "tag" the oligosaccharides to facilitate chromatography and provide a means of detection. Second, MS was shown to give consistent data in interlaboratory comparisons, and it was concluded that MS-based strategies provide the most effective means of both identification and quantitation of N-glycans in glycomics studies.
HGPI has now extended its comparison of analytical methodologies to encompass mucin-type O-glycosylation. In this type of glycosylation, O-glycans are attached by a GalNAc to the amino acids serine and threonine. They can occur as single O-glycans or clustered in mucin domains. Such domains are most abundant in the class of glycoproteins known as mucins, which typically have a great number of mucin domains arranged as tandem repeats, but are also found in many extracellular proteins like IgA, which is the subject of the current study. IgA1 represents one of two structurally and functionally distinct subclasses of IgA (2) . The heavy chains of IgA1 molecules contain a hinge region segment between the first and second constant region domains. This segment, which has a high content of Pro, Ser, and Thr, is the site of attachment of usually up to six O-linked glycan chains (3) (4) (5) (6) (7) (8) (9) . In circulatory IgA1, these O-glycans consist of GalNAc with a ␤1,3-linked Gal; both saccharides may be sialylated (3, 4) . The carbohydrate composition of the O-linked glycans in the hinge region of normal human serum IgA1 is variable. The prevailing forms include Gal-GalNAc disaccharide and its mono-and disialylated forms (4, 5, 10) . Gal-deficient variants with terminal GalNAc or sialylated GalNAc are rarely found in the O-glycans of normal serum IgA1 (5) but are much more common in IgA nephritis patients (11, 12) in whom IgG autoantibodies reactive to the hypogalactosylated IgA1 form immune complexes and lead to mesangioproliferative glomerulonephritis (13) . These pathological features clearly demonstrate the importance of determining the profile of the total glycan pool as an initial but essential step in tackling the complex O-glycan structures. In the present study, IgA1 preparations from three patients with multiple myeloma were delivered by HGPI to 15 experienced academic laboratories, and the results of O-glycomics analysis, especially the total glycoform profiles, obtained using different analytical methodologies were assessed. This study was designed to compare and evaluate various methods differing in sample preparation and analytical modes as well as to document levels of variance or consistency among the data.
EXPERIMENTAL PROCEDURES
Sample Preparation-Three IgA1 myeloma proteins named "NUD," "VDS," and "SapII" were isolated from respective serum samples from three patients with multiple myeloma by precipitation with 50% saturated ammonium sulfate followed by gel filtration chromatography on Sepharose 6B and by ion exchange chromatography on DEAE-cellulose (14, 15) . Purity was assessed by immunoelectrophoresis with rabbit anti-human serum proteins. These samples were provided by one of the authors (K. K.). Each 250-g sample was delivered with dry ice in a solution for NUD at 250 g/ml in 6 M guanidine/HCl, 0.25 M Tris-HCl, 1% dithiothreitol (pH 8.6) and for Sap-II at 2 mg/ml in 20 mM Tris-HCl, 2% NaCl, 0.1% NaN 3 (pH 8.0) or a lyophilized form for VDS.
Analytical Protocols-The analytical methods used by each participating laboratory are given in the supplemental material.
RESULTS AND DISCUSSION
Human IgA1 has both N-and O-glycosylation with the latter being the focus of this study. The O-glycans are located on the hinge region of the heavy chain, and five sites of glycosylation have been identified previously (Thr-225, Thr-228, Ser-230, Ser-232, and Thr-236), two of which (225 and 236) have been reported to be partially occupied (3) (4) (5) (6) The 15 laboratories participating in the study analyzed tryptic glycopeptides, released oligosaccharides, or both. General work flows are shown in Schemes 1 and 2, and methodologies used by each laboratory are summarized in Table I . IgA1 derived from three patients with multiple myeloma (coded NUD, Sap-II, and VDS) (14, 15) were prepared in Japan and dispatched to the participating laboratories in 250-g aliquots. Several of the participating laboratories additionally analyzed a sample of IgA pooled from healthy individuals. Glycopeptide Analysis-MALDI and/or ESI mass fingerprinting of cysteine-alkylated tryptic hinge O-glycopeptides was carried out by six laboratories. Data of remarkable consistency were obtained from most of these laboratories despite the use of a variety of sample handling procedures and mass spectrometric instrumentation (see Table I and supplemental methods). Exemplar MALDI and ESI mass spectra from O-glycopeptides isolated from solution digests using hydrophilic affinity extraction (16) by two laboratories (labs 1 and 4) are shown in Fig. 1 and supplemental Fig. S1 , respectively. The enriched glycopeptide fraction was directly analyzed by MALDI-MS in linear TOF mode (lab 1) or subjected to on-line LC-ESI-MS (lab 4). Profiles obtained from on-line LC-ESI-MS of solution digests and by in-gel digestion followed by LC-ESI-MS are shown in Fig. 2 and supplemental Figs. S2 and S3 (labs 2, 5, and 6, respectively). Some laboratories additionally analyzed a pooled sample of IgA1 purified from healthy individuals. An exemplar mass fingerprint for the hinge glycopeptide of normal IgA1 is shown in supplemental Fig.  S4 . For simplicity, molecular ions of the glycopeptide glycoforms are annotated in all spectra with their predicted oligosaccharide compositions using N, H, and NA to represent HexNAc (GalNAc), Hex (Gal), and NeuAc (N-acetylneuraminic acid), respectively.
Sialylation was prominent in Sap-II, and heterogeneity was small in NUD in all the data sets. However, some differences were also observed. Typically, sialylated glycans were less abundant in the MALDI mass spectra (lab 1) when looking at the ratio of 4N4H/4N4H1NA/4N4H2NA/4N4H3NA in Sap-II (Fig. 3) or that of 4N4H1/4N4H1NA in VDS in Fig. 1 and supplemental Figs. S1 and S2. This was likely due to low efficiency of the ionization of sialylated glycopeptides in the positive ion mode because the underestimation was less prominent in the MALDI mass spectra taken in the negative mode (see supplemental Fig. S5 from lab 1). Loss of sialyl residues is the major drawback of MALDI of oligosaccharides or glycopeptides, and this was observed, even when using the negative ionization mode, especially in the glycopeptide ions with multiple sialic acids: e.g. 5N4H3NA and 4N4H4NA (supplemental Fig. S5 ). However, the extent of sialic acid loss from O-glycans is less prominent than the cases of N-glycans. 2 On the other hand, the results from ESI from three laboratories, lab 2 ( Fig. 2 ), lab 4 (supplemental Fig. S1 ), and lab 5 (supplementary Fig. S2 ), also showed some discrepancies in the sialylated species. As indicated by the ratio of 4N4H to 4N4H1NA of NUD, sialylation levels were higher in the analysis of lab 4 than in those of lab 2 and lab 5. From the mass spectrometric point of view, one issue that should be clarified to address the disagreement is the charge state distribution of the original mass spectra from these laboratories or the charge state of the source mass spectra for deconvolution. Alternatively, the disagreement may be due to the usage of different types of mass analyzers and detectors. In addition, lab 5 reported predominance of small glycans probably due to different sample preparation (Fig. 3) ; lab 5 extracted glycopeptides from SDS-PAGE gels by in-gel digestion.
One laboratory (lab 3) used jacalin lectin chromatography to isolate the glycopeptides, but the yields were found to be insufficient for a comprehensive MS study, and the limited data that were obtained differed substantially from the other laboratories. Considering that this laboratory has sufficient experience of the analysis of hinge O-glycopeptides obtained from a few mg of IgA1, their protocol was not suited for a smaller scale analysis; probably the volume (2 ml) of jacalin was too great to efficiently recover the glycopeptides from the lectin column.
Additional analyses to decrease the complexity of the MS profiles were carried out by lab 1 (supplemental Figs. S6 and S7). Desialylation removed the negative effect of sialic acid on the ionization efficiency in the MALDI, and the small signals corresponding to highly glycosylated glycopeptides with six or seven HexNAc residues could be observed (supplemental Fig. S6 ). The number of O-glycans attached to the glycopeptides was clearly demonstrated by the mass spectra after eliminating peripheral glycans attached to the Ser/ThrGalNAc units by incubation with trifluoromethanesulfonic acid (supplemental Fig. S7) . However, the current protocol of reactions did not guarantee good reproducibility, and some removal of GalNAc residues was observed. Deglycosylation by glycosidase (galactosidase) would be an alternative to this chemical treatment, but the removal of galactose residues was incomplete in a preliminary experiment carried out by lab 1 (data not shown).
The major advantages of glycopeptide analysis are clearly illustrated in this pilot study as follows. First, the average or maximum/minimum number of attached sites can be counted. Second, relative abundances of different glycoform 2 Y. Wada and M. Tajiri, unpublished observations. SCHEME 2. Work flow of various methodologies used for Oglycan structural analysis. Numbers in parentheses are laboratory numbers. 2-AA, 2-aminobenzoic acid.
compositions can be readily established at high sensitivity. Third, MS of glycopeptides does not miss the GalNAc-␣-OSer/Thr (Tn epitope), which is characterized by components having a higher number of HexNAc than Hex such as 5N4H or 5N3H.
Chromatographic Analysis of Tagged O-Glycans-Chromatography of reductively aminated oligosaccharides carrying fluorescent "tags" at their reducing ends is a well established procedure for quantitating mixtures of N-glycans. It remains a popular method despite issues of variance between laboratories (1) because it does not require highly sophisticated and expensive instrumentation. Exploitation of this type of methodology in the O-glycan field is far less common because free reducing sugars are required for the tagging reaction, and no tools are available that are capable of liberating O-glycans efficiently and cleanly from glycopeptides or glycoproteins while retaining their reducing sugars. Unfortunately, no broad spectrum O-glycanase has yet been discovered. Therefore, the release of O-glycans requires base-catalyzed chemical elimination, and it has been known for over 40 years that the core 1 arm of O-glycans is readily "peeled" from the 3-position of the reducing GalNAc residue under basic conditions unless the latter is reduced. Hence, reductive elimination is the only way of obtaining an artifact-free O-glycan population. Nevertheless, chromatographic/tagging methodologies can play a useful role in O-glycan analysis, for example in the analysis of complex mucins (17) , provided peeling products and other chemical artifacts are taken into account in data Work flows and protocols are given in Scheme 2 and supplemental methods, respectively, and typical data are shown in supplemental Figs. S11 and S12. Quantitative information was extracted from MALDI fingerprints and LC-MS profiles by measuring peak heights and peak areas, respectively. With one exception (lab 13; see supplemental methods), no corrections were made for differences in the response factors of the various glycans. Exemplar quantitative data are shown in Table III for permethylated and native samples, respectively, and data from all eight labs are collated in supplemental Figs. S8 -S14. Collectively, these data are broadly in line with the conclusions of the glycopeptide profiling experiments (see above), namely that most of the glycans are core 1 type with monosialylated core 1 dominating in Sap-II and non-sialylated core 1 being the major glycan in VDS and NUD. For technical reasons, the neutral glycans were missed in some of the on-line experiments. On-line graphitized carbon LC will not detect the Tn antigen as single monosaccharides are not retained. Minor core 2 glycans were most reliably observed in the analyses of permethylated samples (supplemental Figs. S11 and S13 for confirmation via tandem MS). A weakness of both methodologies is that monosaccharides such as Tn are difficult to analyze reliably because of masking by matrix peaks in MALDI data and early elution together with impurities in on-line LC-MS.
In summary, the study has shown that both strategies i and ii are reliable strategies for semiquantitative O-glycan analysis except for the analysis of Tn. On the other hand, strategy iii in which native samples were analyzed as mixtures by MS without permethylation or on-line LC purification gave equivocal data. Notably, spectra were characterized by dominant matrix and artifact peaks, and only one molecular ion species was assignable to an authentic IgA O-glycan (see supplemental Fig. S14 ). It was also observed in some experiments that small quantities of glycopeptides (with two or more amino acids) are recovered from reductive elimination reactions, and their presence may need to be taken into account when data are analyzed.
Conclusions-In this study, the O-glycan content of three IgA1 samples was analyzed by 15 participating laboratories.
Six of these laboratories used either MALDI or ESI to obtain mass fingerprints of the hinge glycopeptide (which has up to five occupied O-glycosylation sites), three laboratories eliminated the O-glycans without reduction and then tagged the free reducing ends prior to chromatographic analysis, and nine laboratories used reductive elimination to release the glycans, which were then analyzed by MS after permethylation (five laboratories) or as native glycans by LC-MS (three laboratories) or MS alone (one laboratory). The main conclusions that can be drawn from the study are summarized below.
Tryptic glycopeptides that were purified using comparable chromatographic procedures gave broadly similar mass fin- 
Comparison of Methods for Profiling O-Glycosylation
gerprints irrespective of whether MALDI or ESI was used. It was noted, however, that the more highly sialylated glycoforms were somewhat less abundant in the MALDI fingerprints, suggesting some loss of sialic acid during the analysis. Nevertheless, the fact that most of the sialic acid was preserved demonstrates that MALDI is a suitable tool for profiling sialylated glycoforms provided the linear ion mode is used in the TOF analysis. Semiquantitative assignment of total glycan compositions deduced from ion abundances in the mass fingerprints enabled intersample comparisons with respect to heterogeneity and overall levels of sialylation. The likely presence of the Tn epitope in some of the glycoforms was revealed by compositions rich in HexNAc. The compositional data give clues to site occupancy: for example, the number of sites occupied cannot be greater than the number of HexNAc residues in the glycoform composition, whereas detailed profiling by MS of glycopeptides requires prior knowledge of the glycan structures obtained by other methods such as chromatography of tagged glycans. Electron capture dissociation or electron transfer dissociation MS/MS instrumentation is capable of defining precise glycosylation sites as well as the size or suggested structures of glycans at specific sites (6, 7, 18) . Indeed, FT-MS equipped with electron capture dissociation has also been used for structure determination of Oglycopeptides and shows potential for site analysis (18, 19) .
Chromatographic/tagging methodologies used by three laboratories in this study were found to give a diverse body of data that could not be readily reconciled with the outputs of the more rigorous glycopeptide analyses described above. It was clear from these experiments that peeling during nonreductive alkaline release of O-glycans from glycopeptides, exacerbated by the frequent occurrence of artifactual chromatographic peaks, severely impacts on the reliability of these methodologies for quantitative O-glycomics. It was also apparent that neither automation of glycan release nor the exploitation of nanoparticle technology for capturing the released glycans has improved the efficacy of these methodologies.
On the other hand, there was good consistency among the data derived from samples that were prepared by reductive elimination. Two general strategies were shown to be highly effective for the reproducible analysis of reduced O-glycans: (i) MALDI mass fingerprinting complemented by MALDI or ESI-MS/MS sequencing of mixtures of permethylated glycans and (ii) on-line LC-ESI-MS in the negative ion mode for native samples. The first afforded the highest sensitivity detection of minor components. Both methodologies are routinely semiquantitative, making them ideal for comparative glycomics. Absolute quantification is also achievable with each technology but requires well characterized standards for calibration of mass spectrometry response factors. The lack of readily available quantified glycan standards remains a logjam for quantitative glycomics.
O-Glycans of IgA are relatively simple, lack isomers, and are not densely clustered as normally observed in the mucins. This makes analysis of the glycopeptides after proteolytic degradation ideal. However, in the mucins with more complex and longer oligosaccharides, this approach will be less useful. The O-glycans then have to be alkaline-released. Permethylation followed by direct MALDI-MS and separation by liquid chromatography coupled to ESI-MS analysis are the two methods of choice for the structural characterization of Oglycans in complex mixtures. The permethylation methods used in this study are suitable for neutral and sialic acidcontaining compounds but need to be modified for sulfated oligosaccharides (20) .
The IgA from patients with multiple myeloma is derived from a B-cell clonal population that tends to be almost monoclonal with the progression of the disease. Although the glycosylation of myeloma proteins will thus be more homogenous than is observed in polyclonal IgA from healthy individuals, the O-glycans exhibit a degree of heterogeneity specific for each myeloma protein (7, 10) . The differences observed here probably reflect varying regulation of O-glycosylation in the different B-cell clones. The distribution of O-glycan heterogeneity in NUD, VDS, and SAP-II is comparable to a published analysis of myeloma IgA1 from other sources (7) .
